Development and characterization of novel erythropoiesis stimulating protein (NESP)

British Journal of Cancer

Volumn 84, Issue SUPPL. 1, 2001, Pages 3-10

  Egrie, J C ^a   Browne, J K ^a  

^a AMGEN INC   (United States)

Author keywords

Biological activity; Carbohydrate; Darbepoetin alfa; Erythropoietin; Pharmacokinetics; Review

Indexed keywords

ANTIBODY; CARBOHYDRATE; DARBEPOIETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GROWTH FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SIALIC ACID; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HEMATOCRIT; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARBOHYDRATE CONFORMATION; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ERYTHROPOIESIS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; GLYCOSYLATION; HALF-LIFE; HEMATOCRIT; HUMANS; MICE; N-ACETYLNEURAMINIC ACID; PERITONEAL DIALYSIS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RANDOMIZED CONTROLLED TRIALS; RATS; RECOMBINANT PROTEINS;

EID: 0034997401     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1746     Document Type: Article

References (43)

1. Boissel JP and Bunn HF (1990) Erythropoietin structure-function relationships. In: Dainiak N, Cronkite EP, McCaffrey R, Shadduck RK, eds. The Biology of Hematopoiesis. pp 227-232. New York: Wiley-Liss
2. Broudy VC, Lin N, Egrie J, de Haeen C, Weiss T, Papayannopoulou T and Adamson JW (1988) Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide. Proc Natl Acad Sci USA 85: 6513-6517
3. Browne JK, Cohen AM, Egrie JC, Lai PH, Lin FK, Strickland T, Watson E and Stabbing N (1986) Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol 51: 693-702
4. Cazzola M, Mercuriali F and Brugnara C (1997) Use of recombinant human erythropoietin outside the setting of uremia. Blood 89: 4248-4267
5. Cheetham JC, Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J and Harvey TS (1998) NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nature Struct Biol 5: 861-866
6. Cumming DA (1991) Glycosylation of recombinant protein therapeutics: control and functional implications. Glycobiology 1: 115-130
7. D'Andrea AD, Lodish HF and Wong GG (1989) Expression cloning of the murine erythropoietin receptor. Cell 57: 277-285
8. Davis JM, Arakawa T, Strickland TW and Yphantis DA (1987) Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26: 2633-2638
9. Delorme E, Lorenzini T, Giffin J, Martin F, Jacobsen F, Boone T and Elliott S (1992) Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 31: 9871-9876
10. Dordal MS, Wang FF and Goldwasser E (1985) The role of carbohydrate in erythropoietin action. Endocrinology 116: 2293-2299
11. Dube S. Fisher JW and Powell JS (1988) Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J Biol Chem 263: 17516-17521
12. Egrie JC, Strickland TW, Lane J, Aoki K. Cohen AM, Smalling R, Trail G, Lin FK, Browne JK and Hines DK (1986) Characterization and biological effects of recombinant human erythropoietin. Immunobiology 172: 213-224
13. Egrie JC. Grant JR, Gillies DK, Aoki KH and Strickland TW (1993) The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate J 10: 263
14. Egrie JC, Dwyer E, Lykos M, Hitz A and Browne JK (1997) Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO). Blood 90: 56a (abstract 243)
15. Elliott SG, Lorenzini T, Strickland T, Delorme E and Egrie JC (2000) Rational design of novel erythropoiesis stimulating protein (ARANESP™): a super-sialated molecule with increased biological activity. Blood 96: 82a (abstract 352)
16. Eschbach JW, Egrie JC, Downing MR, Browne JK and Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73-78
17. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR et al (1989) Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111: 992-1000
18. Evans RW, Rader B and Manninen DL (1990) The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 263: 825-830
19. Fukuda MN, Sasaki H, Lopez L and Fukuda M (1989) Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 73: 84-89
20. Goldwasser E, Kung CK and Eliason J (1974) On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem 249: 4202-4206
21. Higuchi M, Oh-eda M, Kuboniwa H, Tomonoh K, Shimonaka Y and Ochi N (1992) Role of sugar chains in the expression of the biological activity of human erythropoietin. J Biol Chem 267: 7703-7709
22. Krantz SB (1991) Erythropoietin. Blood 77:419-434
23. Lacombe C and Mayeux P (1998) Biology of erythropoietin. Haematologica 83: 724-732
24. Lai PH, Everett R, Wang FF, Arakawa T and Goldwasser E (1986) Structural characterization of human erythropoietin. J Biol Chem 261: 3116-3121
25. Lin FK (1987) The molecular biology of erythropoietin. In: Rich IN, (ed) Molecular and cellular aspects of erythropoietin and erythropoiesis, pp. 23-36. New York: Springer
26. Lodish HF, Hilton DJ. Klingmuller U, Watowich SS and Wu H (1995) The erythropoietin receptor: biogenesis, dimerization, and intracellular signal transduction. Cold Spring Harb Symp Quant Biol 60: 93-104
27. Lowry PH, Keighley G and Borsook H (1960) Inactivation of erythropoietin by neuraminidase and mild substitution reactions. Nature 185: 102-103
28. Lukowsky WA and Painter RH (1972) Studies on the role of sialic acid in the physical and biological properties of erythropoietin. Can J Biochem 50: 909-917
29. Macdougall IC. on behalf of the ARANESP™ UK Study Group (1998) Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia, J Am Soc Nephrol 9: 258a-259a (abstract A1317)
30. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J and Egrie J (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients, J Am Soc Nephrol 10: 2392-2395
31. Markham A and Bryson HM (1995) Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 49: 232-254
32. Miyake T, Kung CK and Goldwasser E (1977) Purification of human erythropoietin. J Biol Chem 252; 5558-5564
33. Narhi LO, Arakawa T. Aoki KH, Elmore R, Rohde MF, Boone T and Strickland TW (1991) The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem 266: 23022-23026
34. Recny MA, Scoble HA and Kim Y (1987) Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem 262: 17156-17163
35. Sasaki H, Bothner B, Dell A and Fukuda M (1987) Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA, J Biol Chem 262: 12059-12076
36. Sasaki H, Ochi N, Dell A and Fukuda M (1988) Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. Biochemistry 27: 8618-8626
37. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, Wilson IA and Wiley DC (1984) A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci USA 81: 1779-1783
38. Sowade B, Sowade O, Moecks J, Franke W and Wamke H (1998) The safety of treatment with recombinanl human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med 1: 303-314
39. Spivak JL and Hogans BB (1989) The in vivo metabolism of recombinanl human erythropoietin in the rat. Blood 73: 90-99
40. Syed RS, Reid SW. Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J. Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J and Stroud RM (1998) Efficiency of signalling through cytokine receptors depends critically on receptor orientation, Nature 395: 511-516
41. Takeuchi M, Takasaki S, Miyazaki H, Kalo T, Hoshi S, Kochibe N and Kobata A (1988) Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J Biol Chem 263: 3657-3663
42. Tsuda E, Goto M, Murakami A, Akai K, Ueda M, Kawanishi G, Takahashi N, Sasaki R, Chiba H, Ishihara H et al (1988) Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins, Biochemistry 27: 5646-5654
43. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR and Cotes PM (1986) Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancer 2: 1175-1178